EANS-News: Annual General Meeting of Marseille-Kliniken AG supports positive development of the company
-------------------------------------------------------------------------------- Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- Annual & Special Corporate Meetings Subtitle: - New supervisory board member Prof. Dr. Enderlein elected - Expansion of the authorized capital to 18.7 million - At the request of the administration former board members were not relieved Hamburg (euro adhoc) - 27 January 2012 - Today´s Annual General Meeting, located at the company´s headquarter in Hamburg, approved all significant applications of the administration with a majority of over 90 percent. This represented approximately 65 percent of the share capital. On administration´s recommendation, both former directors, Stefan Herzberg and Dr. Thomas Klaue, were not relieved. Prof. Dr. Dietmar Enderlein was elected to the Supervisory Board. The long-time expert in the health care industry is following Mathias Kampmann, who retired on 17 January 2012. The decision on the creation of new authorized capital was supported by the major shareholder and the representatives of shareholder protection communities. Overall, the meeting took place under the close observation of journalists and numerous experts in health care. "The decisions of our shareholders will create a reliable basis for our operational success.", said Michael Thanheiser, chairman of the company. Further inquiry note: Christian Hillermann Hillermann Consulting Investor Relations for Marseille-Kliniken AG Poststraße 14/16 20354 Hamburg Germany Tel.: +49-(0)40 / 320 279-10 Fax: +49-(0)40 / 320 279-114 www.marseille-kliniken.com end of announcement euro adhoc -------------------------------------------------------------------------------- company: Marseille-Kliniken AG Alte Jakobstraße 79/80 D-10179 Berlin phone: +49 (0)30 246 32-400 FAX: +49 (0)30 246 32-401 mail: info@marseille-kliniken.de WWW: http://www.marseille-kliniken.de sector: Pharmaceuticals ISIN: DE0007783003 indexes: CDAX, Classic All Share, Prime All Share stockmarkets: free trade: Berlin, Düsseldorf, Stuttgart, regulated dealing: Hamburg, regulated dealing/prime standard: Frankfurt language: English
Original-Content von: Marseille-Kliniken AG, übermittelt durch news aktuell